يحاول ذهب - حر
"HSA is adopting a forward-looking 5P Strategy to tackle challenges"
BioSpectrum Asia August 2025
|BioSpectrum Asia
Adjunct Professor (Dr) Raymond Chua, who stepped into his role as CEO of Singapore’s Health Sciences Authority (HSA) in December 2024, outlines the agency’s current priorities in positioning Singapore as a regional hub for biotech and medtech innovation.
 
 Adjunct Professor (Dr) Raymond Chua, CEO, Health Sciences Authority (HSA), Singapore
As one of the world’s leading regulatory bodies, HSA is balancing rigorous safety oversight with the need to support emerging technologies like cell, tissue and gene therapy products (CTGTP) and AI-driven medical tools. He also discusses HSA’s collaboration with international regulators to align standards and enable faster, cross-border access to new health technologies, and how the agency is preparing to meet the biggest regulatory challenges of the next five years. Edited excerpts:
Presently, what are HSA's key priorities that align with positioning Singapore as a regional hub for biotech and medtech innovation?
We see ourselves as more than just a regulator. We are an enabler of innovation, a partner in progress. Science and technology have always been central to Singapore's growth story, and our role is to make sure that regulatory frameworks keep pace with the exciting developments in biotech and medtech.
In this fast-moving era — marked by breakthroughs in Artificial Intelligence, regenerative therapies, and digital health — we're focused on keeping our regulatory system robust, efficient, and yet agile. Our key priority is to ensure that Singapore remains not just a safe harbour for health products, but a launchpad for innovation.
We are working closely with our economic agencies, industry partners and healthcare institutions to build an innovative access framework. This will allow for earlier, deeper engagement with the industry and healthcare institutions, from the clinical trial stage right through to market entry. The objective is clear: accelerate access to promising health products and new technologies while upholding high standards of safety and quality.
هذه القصة من طبعة BioSpectrum Asia August 2025 من BioSpectrum Asia.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من BioSpectrum Asia
 
 BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium
Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Korea makes smart patch that can run tests using sweat instead of blood
A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka
The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines
China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.
1 min
BioSpectrum Asia Oct 2025
Listen
Translate
Change font size

